Famotidine, a potent second-generation receptor inhibitor, exerts its therapeutic effect by selectively binding to and reversing histamine H2 receptors located on gastric cells within the stomach lining. This binding prevents histamine from activating adenylate cyclase, an enzyme responsible for producing cyclic AMP (cyclic adenosine monophosphate)